Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.97 USD
-0.04 (-4.15%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.96 -0.01 (-0.83%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADIL 0.97 -0.04(-4.15%)
Will ADIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ADIL
Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)
Adial Pharmaceuticals reports Q2 results
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals reports Q2 net loss $2.5M vs $1.1M last year
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025